Aim Hepatic toxicity of chemotherapy for colorectal cancer and its complications after hepatic
metastasis surgery are unclear. Studies reporting hepatic lesions after chemotherapy for …

Approximately 50% of patients with colorectal cancer will develop liver metastases.
Complete resection is associated with 50% five-year overall survival and 20% long-term …

4082 Background: Combining bevacizumab with XELOX/FOLFOX4 is inreasingly being
recognized as state of the art in the neoadjuvant treatment of colorectal cancer liver …

Effective systemic drugs are increasingly used to treat patients with colorectal liver
metastases. Recent trials have shown that chemotherapy can reduce the size of metastases …

AIMS: The aim of this article is to review the current state of knowledge in relation to the
development of chemotherapy associated steatohepatitis (CASH) and sinusoidal obstruction …

Chemotherapy-associated hepatotoxicity in liver metastatic colorectal cancer is attracting
more and more attention for clinicians. This hepatotoxicity heralds an increased risk of …

Colorectal cancer patients with isolated liver metastasis are potentially cured with surgical
resection. Recent advances in systemic chemotherapy have increased the ability to convert …

AIM: The aim of this study was to assess chemotherapy associated hepatotoxicity after 3
months' treatment and to correlate patterns of hepatotoxicity with perioperative morbidity …

Modern combination chemotherapies, mainly including oxaliplatin or irinotecan, have
demonstrated a significant increase in response rates. This led to the concept of down-sizing …

Background: Improved efficacy of chemotherapy for treatment of colorectal liver metastases
(CLM) has renewed interest in the use of systemic treatment as part of a 'potentially …